



Prograf® (tacrolimus) – Expanded indication

- On July 16, 2021, the FDA approved Astellas Pharma's Prograf (tacrolimus), for the prophylaxis of organ rejection, in adult and pediatric patients receiving lung transplant in combination with other immunosuppressants.
 - Prograf is also approved for the prophylaxis of organ rejection, in adult and pediatric patients receiving allogeneic kidney transplant, liver transplant, or heart transplant.
- The efficacy and safety of Prograf-based immunosuppression in primary lung transplantation were assessed in a noninterventional (observational) study using data from the U.S. Scientific Registry of Transplant Recipients. The study analyzed outcomes based on discharge immunosuppression treatment regimen in recipients of a primary lung transplant between 1999 and 2017 who were alive at the time of discharge.
 - In adult patients receiving tacrolimus immediate-release products in combination with mycophenolate mofetil (MMF) (n = 15,478) or tacrolimus immediate-release products in combination with azathioprine (AZA) (n = 4,263), the one-year graft survival estimates from time of discharge were 90.9% and 90.8%, respectively.
 - In pediatric patients receiving tacrolimus immediate-release products in combination with MMF (n = 450) or tacrolimus immediate-release products in combination with AZA (n = 72), the one-year graft survival estimates from time of discharge were 91.7% and 84.7%, respectively.
- Prograf carries a boxed warning for malignancies and serious infections.
- Refer to the Prograf drug label for complete dosing and administration recommendations in lung transplant as well as its other uses.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](https://www.optum.com).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2021 Optum, Inc. All rights reserved.